The Clinical Outcomes, Prognostic Factors and Nomogram Models for Primary Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy

被引:5
作者
Luo, Li-Mei [1 ,2 ]
Wang, Ying [1 ,2 ]
Lin, Pei-Xian [3 ]
Su, Chuang-Huang [4 ]
Huang, Bao-Tian [2 ]
机构
[1] Shantou Univ, Dept Radiat Oncol, Coll Med, Shantou, Peoples R China
[2] Canc Hosp Shantou Univ, Dept Radiat Oncol, Coll Med, Shantou, Peoples R China
[3] Shantou Univ, Affiliated Hosp 2, Coll Med, Dept Nosocomial Infect Management, Shantou, Peoples R China
[4] Shantou Cent Hosp, Dept Radiat Oncol, Shantou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
基金
中国国家自然科学基金;
关键词
stereotactic body radiation therapy; primary lung cancer; clinical outcomes; prognostic factors; nomogram model; ABLATIVE RADIOTHERAPY; TARGET VOLUME; LOCAL-CONTROL; CARCINOMA; SURVIVAL; TRIAL;
D O I
10.3389/fonc.2022.863502
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PurposeStereotactic body radiation therapy (SBRT) is a standard treatment for early primary lung cancer patients. However, there are few simple models for predicting the clinical outcomes of these patients. Our study analyzed the clinical outcomes, identified the prognostic factors, and developed prediction nomogram models for these patients. Materials and MethodsWe retrospectively analyzed 114 patients with primary lung cancer treated with SBRT from 2012 to 2020 at our institutions and assessed patient's clinical outcomes and levels of toxicity. Kaplan-Meier analysis with a log-rank test was used to generate the survival curve. The cut-off values of continuous factors were calculated with the X-tile tool. Potential independent prognostic factors for clinical outcomes were explored using cox regression analysis. Nomograms for clinical outcomes prediction were established with identified factors and assessed by calibration curves. ResultsThe median overall survival (OS) was 40.6 months, with 3-year OS, local recurrence free survival (LRFS), distant disease-free survival (DDFS) and progression free survival (PFS) of 56.3%, 61.3%, 72.9% and 35.8%, respectively, with grade 3 or higher toxicity rate of 7%. The cox regression analysis revealed that the clinical stage, immobilization device, and the prescription dose covering 95% of the target area (D95) were independent prognostic factors associated with OS. Moreover, the clinical stage, and immobilization device were independent prognostic factors of LRFS and PFS. The smoking status, hemoglobin (Hb) and immobilization device were significant prognostic factors for DDFS. The nomograms and calibration curves incorporating the above factors indicated good predictive accuracy. ConclusionsSBRT is effective and safe for primary lung cancer. The prognostic factors associated with OS, LRFS, DDFS and PFS are proposed, and the nomograms we proposed are suitable for clinical outcomes prediction.
引用
收藏
页数:14
相关论文
共 37 条
  • [1] Nomograms in oncology: more than meets the eye
    Balachandran, Vinod P.
    Gonen, Mithat
    Smith, J. Joshua
    DeMatteo, Ronald P.
    [J]. LANCET ONCOLOGY, 2015, 16 (04) : E173 - E180
  • [2] Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries
    Baumann, Pia
    Nyman, Jan
    Lax, Ingmar
    Friesland, Signe
    Hoyer, Morten
    Ericsson, Suzanne Rehn
    Johansson, Karl-Axel
    Ekberg, Lars
    Morhed, Elisabeth
    Paludan, Merete
    Wittgren, Lena
    Blomgren, Henrik
    Lewensohn, Rolf
    [J]. ACTA ONCOLOGICA, 2006, 45 (07) : 787 - 795
  • [3] Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy
    Baumann, Pia
    Nyman, Jan
    Hoyer, Morten
    Wennberg, Berit
    Gagliardi, Giovanna
    Lax, Ingmar
    Drugge, Ninni
    Ekberg, Lars
    Friesland, Signe
    Johansson, Karl-Axel
    Lund, Jo-Asmund
    Morhed, Elisabeth
    Nilsson, Kristina
    Levin, Nina
    Paludan, Merete
    Sederholm, Christer
    Traberg, Anders
    Wittgren, Lena
    Lewensohn, Rolf
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3290 - 3296
  • [4] PROSPECTIVE, RISK-ADAPTED STRATEGY OF STEREOTACTIC BODY RADIOTHERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CANCER: RESULTS OF A PHASE II TRIAL
    Bral, Samuel
    Gevaert, Thierry
    Linthout, Nadine
    Versmessen, Harijati
    Collen, Christine
    Engels, Benedikt
    Verdries, Douwe
    Everaert, Hendrik
    Christian, Nicolas
    De Ridder, Mark
    Storme, Guy
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05): : 1343 - 1349
  • [5] X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Camp, RL
    Dolled-Filhart, M
    Rimm, DL
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (21) : 7252 - 7259
  • [6] Caro JJ, 2001, CANCER-AM CANCER SOC, V91, P2214, DOI 10.1002/1097-0142(20010615)91:12<2214::AID-CNCR1251>3.0.CO
  • [7] 2-P
  • [8] Prognostic factors of local control and disease free survival in centrally located non-small cell lung cancer treated with stereotactic body radiation therapy
    Duijm, Marloes
    van der Voort van Zyp, Noelle C.
    Granton, Patrick V.
    van de Vaart, Paul
    Mast, Mirjam E.
    Oomen-de Hoop, Esther
    Hoogeman, Mischa S.
    Nuyttens, Joost J.
    [J]. ACTA ONCOLOGICA, 2020, 59 (07) : 809 - 817
  • [9] Size matters: A comparison of T1 and T2 peripheral non-small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)
    Dunlap, Neal E.
    Larner, James M.
    Read, Paul W.
    Kozower, Benjamin D.
    Lau, Christine L.
    Sheng, Ke
    Jones, David R.
    [J]. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2010, 140 (03) : 583 - 589
  • [10] Non-Small Cell Lung Cancer, Version 1.2020 Featured Updates to the NCCN Guidelines
    Ettinger, David S.
    Wood, Douglas E.
    Aggarwal, Charu
    Aisner, Dara L.
    Akerley, Wallace
    Bauman, Jessica R.
    Bharat, Ankit
    Bruno, Debora S.
    Chang, Joe Y.
    Chirieac, Lucian R.
    D'Amico, Thomas A.
    Dilling, Thomas J.
    Dobelbower, Michael
    Gettinger, Scott
    Govindan, Ramaswamy
    Gubens, Matthew A.
    Hennon, Mark
    Horn, Leora
    Lackner, Rudy P.
    Lanuti, Michael
    Leal, Ticiana A.
    Lin, Jules
    Loo, Billy W., Jr.
    Martins, Renato G.
    Otterson, Gregory A.
    Patel, Sandip P.
    Reckamp, Karen L.
    Riely, Gregory J.
    Schild, Steven E.
    Shapiro, Theresa A.
    Stevenson, James
    Swanson, Scott J.
    Tauer, Kurt W.
    Yang, Stephen C.
    Gregory, Kristina
    Hughes, Miranda
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (12): : 1464 - 1472